Urolog. pro Praxi, 2009; 10(6): 336-338

Hormonal therapy for prostate cancer

MUDer. Jan Jansa, prof. MUDr. Jiří Petera, Ph.D
Klinika onkologie a radioterapie FN a LF UK Hradec Králové

Hormonal manipulation in management of prostate cancer is nowadays considered the treatment of choice not only for advanced and

metastatic disease, but there are many other settings in which hormonal therapy is used. However, it is necessary to understand context

of multimodal treatment approach and it is essential to prefer such approach which is beneficial for prolongation of survival and

preserve quality of life.

Keywords: hormonal therapy, prostate cancer.

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jansa MJ, Petera J. Hormonal therapy for prostate cancer. Urol. praxi. 2009;10(6):336-338.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240. Go to original source... Go to PubMed...
    2. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-223. Go to original source...
    3. Belej K, Kaplan O. Hormonální regulace a možnosti jejího ovlivnění v léčbě karcinomu prostaty. Urolog. pro Praxi 2008; 9(1): 10-15.
    4. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95(2): 361-376. Go to original source... Go to PubMed...
    5. Wirth M, Tyrrell C, Delaere K, et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years´ follw-up. Prostate Cancer Prostatic Dis 2007; 10: 87-93. Go to original source... Go to PubMed...
    6. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; 4: CD006019. Go to original source...
    7. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97(2): 247-254. Go to original source... Go to PubMed...
    8. Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004; 172(5Pt1): 1871-1876. Go to original source... Go to PubMed...
    9. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7(6): 472-479. Go to original source... Go to PubMed...
    10. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich M. Short-term neodajuvant androgen deprivation therapy and external-beam radiotherapy for localy advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol 2008; 26(4): 585-591. Go to original source... Go to PubMed...
    11. Bolla M, Collette L, Van Tienhoven G, Warde W, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Piérart M. Ten year resulst of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy; a phase III EORTC study. Int J Radiat Oncol Biol Phys 2008; 72(1 Suppl 1): S30-S31. Go to original source...
    12. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61(5): 1285-1290. Go to original source... Go to PubMed...
    13. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group. RTOG 92-02: Phase III trial of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol 2003; 21(21): 3972-3978. Go to original source... Go to PubMed...
    14. Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA. Long term outcome following threedimensional conformal/intensity modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008; 53(6): 1172-1179. Go to original source... Go to PubMed...
    15. Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, Jonas U. Long-term results of interstitial brachytherapy (LDR-brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006; 24(3): 289-295. Go to original source... Go to PubMed...
    16. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79(2): 235-246. Go to original source... Go to PubMed...
    17. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predátor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24(24): 3984-3990. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.